- Home
- ALNY vs RGC Comparison
ALNY vs RGC Comparison
Compare ALNY & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- RGC
- Stock Information
- Founded
- ALNY 2002
- RGC 2014
- Country
- ALNY United States
- RGC Hong Kong
- Employees
- ALNY N/A
- RGC N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- RGC Medicinal Chemicals and Botanical Products
- Sector
- ALNY Health Care
- RGC Health Care
- Exchange
- ALNY Nasdaq
- RGC Nasdaq
- Market Cap
- ALNY 40.4B
- RGC 38.6B
- IPO Year
- ALNY 2004
- RGC 2021
- Fundamental
- Price
- ALNY $320.87
- RGC $17.41
- Analyst Decision
- ALNY Strong Buy
- RGC
- Analyst Count
- ALNY 24
- RGC 0
- Target Price
- ALNY $341.91
- RGC N/A
- AVG Volume (30 Days)
- ALNY 863.4K
- RGC 2.8M
- Earning Date
- ALNY 07-31-2025
- RGC 06-30-2025
- Dividend Yield
- ALNY N/A
- RGC N/A
- EPS Growth
- ALNY N/A
- RGC N/A
- EPS
- ALNY N/A
- RGC N/A
- Revenue
- ALNY $2,348,099,000.00
- RGC N/A
- Revenue This Year
- ALNY $30.77
- RGC N/A
- Revenue Next Year
- ALNY $30.51
- RGC N/A
- P/E Ratio
- ALNY N/A
- RGC N/A
- Revenue Growth
- ALNY 17.21
- RGC N/A
- 52 Week Low
- ALNY $205.87
- RGC $0.08
- 52 Week High
- ALNY $333.70
- RGC $83.60
- Technical
- Relative Strength Index (RSI)
- ALNY 57.52
- RGC 47.37
- Support Level
- ALNY $314.10
- RGC $9.39
- Resistance Level
- ALNY $328.99
- RGC $30.00
- Average True Range (ATR)
- ALNY 9.40
- RGC 9.01
- MACD
- ALNY -1.23
- RGC -1.91
- Stochastic Oscillator
- ALNY 52.48
- RGC 14.05
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.